Cervical CancerCuPRACNCT05947513
Concomitant Curcumin Palliative Radiotherapy in Advanced Cervical Cancer Trial
A study testing Curcumin and Palliative radiotherapy in people with Cervical Cancer, run by Addis Ababa University at 1 site in Ethiopia.
Trial summary
The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are: 1. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Cervical Cancer
- What is being tested?
- Curcumin and Palliative radiotherapy
- Type of treatment
- Pill or oral medicine, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 27 participants
- Where
- 1 siteEthiopia
- Study dates
- 10 Apr 2025to Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 years old (Adult, Older Adult)
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA
- Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
- Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500/mm3; platelet count ≥100.000/mm3; hemoglobin ≥10.0 g/dL); renal function (serum creatinine ≤1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL/min)
- Participants must have measureable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) V1.1.
- Agree to use an effective form of contraception (e.g., true abstinence (not periodic abstinence), barrier contraception, highly effective hormonal contraception) if the participant is of child bearing age
- Give informed consent
Who cannot join
- Cervical cancer patients who are candidates for single dose palliative radiotherapy
- Patients with severe or bilateral hydronephrosis
- Evidence of distant metastases
- Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment
- Received any previous radiation or chemotherapy for cervical cancer
- Underwent surgery in the four weeks prior to the enrolment date or scheduled to undergo surgery within eight weeks after end of treatment
Show all 12Show fewer
- Currently using of any chemotherapy or scheduled to receive within eight weeks after end of treatment
- Known allergy to turmeric or its derivatives (ginger, curry, cumin, or cardamom)
- Known allergy to fenugreek, peanut, soy, lentil, pea, bean, and chickpea
- Presence of conditions that precludes the safe administration of the trial intervention and/or prohibit adequate compliance to study requirements including chronic ongoing infections (like HIV, Hepatitis B or C), uncontrolled hypertension, heart failure, cardiac arrhythmia, unstable angina, chronic obstructive lung disease, diabetes mellitus, chronic renal disease, chronic liver disease, biliary tract obstruction or cholelithiasis, gastric or duodenal ulcers, autoimmune or inflammatory disorders, a coagulation or platelet disorder, seizure disorders and psychiatric illness. Patients with disorders other than the ones specified above may also be excluded based on the judgment of the principal investigator.
- Pregnant and breastfeeding women
- Participants with circumstances that will not permit completion of the study or required follow-up. For instance, if travel to and from treatment site is an issue.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Ethiopia1 site, 1 recruiting
- Recruiting
Tikur Anbessa Specialized Hospital
Addis Ababa
Wondemagegnehu Tignehe, MD, tigeneh@yahoo.com
About this study
Official title: Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial
The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are:
- Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible?
- Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses?
- Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe?
- How much curcumin is absorbed into the body and how long will it stay in the body?
Read more
Participants will:
- Take 250 mg curcumin capsules four times per day for 4-6 weeks in addition to the prescribed palliative radiotherapy. ii. Provide blood and urine samples for laboratory tests. iii. Provide blood samples to measure curcumin levels in their body. iv. Obtain CT-scan to measure their tumor response. v. Complete questioners to measure improvements to their quality of life, if any.
- Conditions
- Cervical Cancer
- Being tested
- Curcumin, Palliative radiotherapy
- Keywords
- Curcumin, Cervical cancer, Radiosensitizer
- Medical subject headings
- Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CurcuminDrug
Also called Curcumagalactomannoside (CGM), CurQfen
Curcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds.
Palliative radiotherapyRadiation
Also called Non-radical radiotherapy
As per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks.
| Study group | Role | What they receive |
|---|---|---|
| Concurrent Curcumin Palliative Radiotherapy | Experimental | Daily 1000 mg oral CGM Curcumin in four divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy. Receives: Drug: Curcumin; Radiation: Palliative radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Treatment Fidelity Rate
Proportion of participants who received the study treatment as planned
Measured: From initiation (Day 1) up to end of treatment over 4-6 weeks
Objective Response Rate (ORR)
Objective Response Rate is defined as proportion of participants having a complete response (CR) or partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Measured: Time Frame: 13-17 weeks
Secondary outcomes (17)
Incidence of Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
Any new or worsening of a pre-existing untoward sign, symptom, or disease, including a clinically significant laboratory or vital sign abnormality during study treatment, is defined as a treatment emergent adverse event
Measured: Up to 10-14 weeks from treatment initiation
Incidence of Dose Reduction in curcumin and radiotherapy regimens
Incidence of Dose A dose reduction is a decrease in dose from the protocol planned starting dose or a decrease from the previous non-zero dose, even if this decrease has been directly preceded by an interruption in curcumin and radiotherapy regimens
Measured: : From initiation (Day 1) up to end treatment over 4-6 weeks
Incidence of Dose Interruption in curcumin and radiotherapy regimens
A Dose Interruption is defined a zero dose given on one or more days on which the protocol-specified dose is non-zero, followed by resumption of dosing
Measured: From initiation (Day 1) up to end treatment over 4-6 weeks
Dose Intensity (DI) of curcumin and radiotherapy
Dose intensity is defined as cumulative dose divided by the treatment duration in weeks
Measured: From initiation (Day 1) up to end treatment over 4-6 weeks
Relative Dose Intensity (RDI) of curcumin and radiotherapy
Relative dose intensity is defined as dose intensity (actual DI) divided by the protocol weekly dose (planned DI), expressed as a percentage.
Measured: From initiation (Day 1) up to end treatment over 4-6 weeks
Disease Control Rate (DCR)
Disease control rate (DCR): proportion of participants having a complete response (CR) or partial response (PR) or stable disease (SD) as defined by the RECIST 1.1 criteria.
Measured: 13-17 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 7-9 weeks
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
Measured: Baseline, 7-9 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 13-17 weeks
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) measures quality of life in cancer patients by evaluating physical, psychological, and social functions. Possible scores range from zero to 100, with a higher scale score indicating a higher response level. As such, high scores on functional and global health status (QoL) scales indicate healthy levels of functioning and high quality of life, respectively. However, a high score on the symptoms scale or item indicates more problems or symptomatology.
Measured: Baseline, 13-17 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 7-9 weeks
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
Measured: Baseline, 7-9 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 13-17 weeks
The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Cervical Cancer Module (EORTC QLQ-CX24) measures quality of life in cervical cancer patients in combination with the QLQ-C30. Possible scores range from zero to 100 for all scale and single-item measures. While a high score on the functional single-items indicates a high degree of functioning, a high score on the symptom scales or single-items indicates a high level of symptomatology or difficulties.
Measured: Baseline, 13-17 weeks
Peak Plasma Concentration (Cmax) of CGM Curcumin
Peak Plasma Concentration represents the highest observed curcumin concentration observed in plasma over all PK sample concentrations following single-dose CGM Curcumin administration.
Measured: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Time to Peak Plasma Concentration (Tmax) of CGM Curcumin
Time to Peak Plasma Concentration (Tmax) represents the time when Cmax of curcumin occurs following single-dose CGM Curcumin administration.
Measured: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Area under the Plasma Concentration versus Time Curve (AUCτ) of CGM Curcumin
Area under the Plasma Concentration versus Time Curve (AUCτ) represents the area under the concentration-time curve of curcumin from time zero to the time of the end of dosing interval following single-dose CGM Curcumin administration.
Measured: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Half-life (T1/2) of CGM Curcumin
Half-life (T1/2) represents the time for plasma concentration of curcumin to fall by a factor of one-half in the terminal phase following single-dose CGM Curcumin administration.
Measured: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Recruitment Rate
Recruitment Rate is defined as the proportion of those who participate in the trial who were approached as potential participants.
Measured: through study completion, an average of 1 year
Assessment Completion Rate
Assessment Completion Rate is defined as the proportion of assessments that could be completed as planned.
Measured: through study completion, an average of 1 year
Attrition Rate
Attrition Rate is defined as the proportion of participants who withdraw from the study.
Measured: through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Jul 2023
- Study start10 Apr 2025
- Primary completionFeb 2026 (estimated)
- Study completionApr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cervical CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 27 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Addis Ababa University
- Sponsor type
- University, hospital or other
- Collaborators
- Akay Natural Ingredients Private Limited
- Responsible party
- Principal investigator, Biniyam Girma, Addis Ababa University
- Investigators
- Eyasu Makonnen, Bpharm, PhD, Study chair, Addis Ababa UniversityBiniyam Girma, Bpharm, MSc, Study director, Addis Ababa UniversityWondemagegnehu Tigeneh, MD, MMed(RT), Principal investigator, Addis Ababa University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05947513
- Sponsor's protocol ID
- 001/21/SoP
- Acronym
- CuPRAC
- Status last verified
- Apr 2025
- First submitted
- 21 Jun 2023
- Last updated
- 20 Apr 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility, Safety, and Efficacy of Concomitant Curcumin in Patients Undergoing Palliative Radiotherapy for FIGO Stage IIIB-IVA Cervical Cancer: An Open-label Pilot Trial
- ClinicalTrials.gov ID
- NCT05947513
- Acronym / sponsor ID
- CuPRAC / 001/21/SoP
- Conditions
- Cervical Cancer
- Keywords
- Curcumin, Cervical cancer, Radiosensitizer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 27 participants (estimated)
- Lead sponsor
- Addis Ababa UniversityUniversity, hospital or other
- Collaborators
- Akay Natural Ingredients Private Limited
- Study start
- 10 Apr 2025 (actual)
- Primary completion
- Feb 2026 (estimated)
- Study completion
- Apr 2026 (estimated)
- First posted
- 17 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to test curcumin as an adjunct treatment in patients with cervical cancer receiving standard-of-care palliative radiation. The main questions it aims to answer are:
- Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients feasible? Is conducting this study feasible?
- Does adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients improve therapeutic responses?
- Is adding curcumin to standard-of-care palliative radiotherapy of cervical cancer patients safe?
- How much curcumin is absorbed into the body and how long will it stay in the body?
Participants will:
- Take 250 mg curcumin capsules four times per day for 4-6 weeks in addition to the prescribed palliative radiotherapy. ii. Provide blood and urine samples for laboratory tests. iii. Provide blood samples to measure curcumin levels in their body. iv. Obtain CT-scan to measure their tumor response. v. Complete questioners to measure improvements to their quality of life, if any.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Concurrent Curcumin Palliative Radiotherapy | Experimental | Drug: Curcumin, Radiation: Palliative radiotherapyDaily 1000 mg oral CGM Curcumin in four divided doses for seven days prior to the start of and for three to five weeks concurrently with palliative radiotherapy. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Age >18 years old (Adult, Older Adult)
- Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IIIB-IVA
- Undergoing for standard of care palliative radiotherapy without chemotherapy as per the local treatment guideline
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2
- Adequate liver function (aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 x ULN (Upper Limit of Normal); total serum bilirubin ≤1.5 x ULN); blood cell counts (absolute neutrophils count ≥1.500/mm3; platelet count ≥100.000/mm3; hemoglobin ≥10.0 g/dL); renal function (serum creatinine ≤1.5 x ULN; estimate creatinine clearance (Cockcroft-Gault) ≥60 mL/min)
Key exclusion criteria (12 listed)
- Cervical cancer patients who are candidates for single dose palliative radiotherapy
- Patients with severe or bilateral hydronephrosis
- Evidence of distant metastases
- Receiving any other investigational agent concurrently or within the last 4 weeks before enrollment
- Received any previous radiation or chemotherapy for cervical cancer
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CurcuminAlso: Curcumagalactomannoside (CGM), CurQfenCurcumin formulation with enhanced bioavailability which contains food-grade curcumin 35% (w/w) combined with the galactomannan fiber from fenugreek seeds. | Drug | Concurrent Curcumin Palliative Radiotherapy |
| Palliative radiotherapyAlso: Non-radical radiotherapyAs per the treatment guidelines of the Tikur Anbessa Hospital Radiotherapy Center, standard-of-care palliative or non-radical radiotherapy entails treatment of advanced cervical cancer patients at a biologically effective dose of 45-55 Gy over the course of three to five weeks. | Radiation | Concurrent Curcumin Palliative Radiotherapy |
Primary outcome
Treatment Fidelity Rate
Time frame: From initiation (Day 1) up to end of treatment over 4-6 weeks
Proportion of participants who received the study treatment as planned
Objective Response Rate (ORR)
Time frame: Time Frame: 13-17 weeks
Objective Response Rate is defined as proportion of participants having a complete response (CR) or partial response (PR) as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
17 secondary outcomes
Incidence of Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v5.0
Time frame: Up to 10-14 weeks from treatment initiation
Incidence of Dose Reduction in curcumin and radiotherapy regimens
Time frame: : From initiation (Day 1) up to end treatment over 4-6 weeks
Incidence of Dose Interruption in curcumin and radiotherapy regimens
Time frame: From initiation (Day 1) up to end treatment over 4-6 weeks
Dose Intensity (DI) of curcumin and radiotherapy
Time frame: From initiation (Day 1) up to end treatment over 4-6 weeks
Relative Dose Intensity (RDI) of curcumin and radiotherapy
Time frame: From initiation (Day 1) up to end treatment over 4-6 weeks
Disease Control Rate (DCR)
Time frame: 13-17 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 7-9 weeks
Time frame: Baseline, 7-9 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-C30 at 13-17 weeks
Time frame: Baseline, 13-17 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 7-9 weeks
Time frame: Baseline, 7-9 weeks
Change from baseline in Health-Related Quality of Life (QOL) as assessed using EORTC QLQ-CX24 at 13-17 weeks
Time frame: Baseline, 13-17 weeks
Peak Plasma Concentration (Cmax) of CGM Curcumin
Time frame: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Time to Peak Plasma Concentration (Tmax) of CGM Curcumin
Time frame: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Area under the Plasma Concentration versus Time Curve (AUCτ) of CGM Curcumin
Time frame: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Half-life (T1/2) of CGM Curcumin
Time frame: Day 1: pre-dose, 30 minutes, 1 hour, 1.5 hours, 2 hours, 4 hours and 6 hours post-dose; Day 6: 30 minutes before the next daily dose, and 1 hour post- dose
Recruitment Rate
Time frame: through study completion, an average of 1 year
Assessment Completion Rate
Time frame: through study completion, an average of 1 year
Attrition Rate
Time frame: through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Apr 2025.
- Individual participant dataSharing planned: No
Related trials for Cervical Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
Proton Re-irradiation in Patients With Recurrent or Second Primary Head and Neck Cancer , a Multicentre Phase II Single Arm Trial
Head & Neck Cancer
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 2
Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial
Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma
RecruitingPhase 4
Lidocaine Infiltration and Neuroimmunomodulation in Head and Neck Cancer Surgery
Head and Neck Cancer (H&N)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Eyasu Makonnen, Bpharm, PhD study chair
Addis Ababa University
Biniyam Girma, Bpharm, MSc study director
Addis Ababa University
Wondemagegnehu Tigeneh, MD, MMed(RT) principal investigator
Addis Ababa University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Curcumin and Palliative radiotherapy in people with Cervical Cancer, run by Addis Ababa University at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Biniyam Girma, Bpharm, MSc (093-708-9518 ext. 251, biniyam.girma@ju.edu.et), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Treatment Fidelity Rate (time frame: From initiation (Day 1) up to end of treatment over 4-6 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2025.